Bayer Aktiengesellschaft (BCBA:BAYN)
Argentina · Delayed Price · Currency is ARS | Market Cap | 84.98T +92.3% |
| Revenue (ttm) | 76.80T -1.7% |
| Net Income | -2.94T |
| EPS | -1,019.64 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.65 |
| Dividend | 40.36 (0.15%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 282 |
| Open | 27,300 |
| Previous Close | 26,320 |
| Day's Range | 26,500 - 27,300 |
| 52-Week Range | 25,800 - 33,000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer Aktiengesellschaft Quarterly report: Q3 2026
Bayer Aktiengesellschaft has published its Q3 2026 quarterly earnings report on November 3, 2026.
Bayer Aktiengesellschaft Slides: Q3 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Bayer Aktiengesellschaft Earnings release: Q3 2026
Bayer Aktiengesellschaft released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Roundup settlement expected before Christmas, Bayer CEO says
German drugs and agrochemicals group Bayer is expecting a $7.25 billion settlement on its Roundup weedkiller to come before Christmas, CEO Bill Anderson said on Tuesday.
Bayer Aktiengesellschaft Earnings Call Transcript: Q3 2026
Nine-month organic sales rose 3% and adjusted EBITDA 7%, with Pharma leading Q3. Guidance increased for adjusted EBITDA and free cash flow, while litigation payments kept free cash flow negative.
Bayer Aktiengesellschaft Earnings release: Q3 2026
Bayer Aktiengesellschaft released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Bayer Posts Narrower Loss In Q3; Improves Full-year Outlook
(RTTNews) - Bayer AG (BYR.L, BAY.MI, BAYN.DE) reported a third quarter net loss attributable to stockholders of 672 million euros compared to a loss of 963 million euros, previous year. Loss per share...
Bayer Raises Earnings Outlook on Pharma Recovery
The German group posted a recovery in its pharma arm after strong demand for key drugs allowed it to offset market pressures at its agricultural and consumer-health divisions.
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
US jury backs Bayer in weedkiller cancer case
A US jury has sided with the multinational company Bayer over three women’s claims its Roundup weedkiller caused their cancer, the latest blow to plaintiffs in thousands of similar cases.
Bayer's Monsanto Wins First Roundup Trial Since Supreme Court's Durnell Ruling, Shares Up
LEVERKUSEN (dpa-AFX) - German life sciences company Bayer AG (BAYN.DE) announced on Friday that its Monsanto unit secured a unanimous defense verdict in the first Roundup-related trial, since the ...
Market One Media Group Inc.: Market One Minute Feature on BNN Bloomberg: MustGrow Biologics and Bayer AG Discusses Validation of Its TerraMG Biocontrol Technology
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2026) - Market One ("Market One"), a marketing agency for public companies, shares editorial and video features on emerging growth stories...
Market One Minute Feature on BNN Bloomberg: MustGrow Biologics and Bayer AG Discusses Validation of Its TerraMG Biocontrol Technology
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2026) - Market One ("Market One"), a marketing agency for public companies, shares editorial and video features on emerging growth stories ac...
MustGrow and Bayer advance mustard-based biocontrol in Europe, the Middle East, and Africa
Colin Bletsky, COO and Director of MustGrow Biologics Corp., and Ralf Glaubitz, Head of Crop Protection Product Team Biologicals at Bayer AG, discuss the Saskatoon-based agricultural biotechnology com...
Bayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual Meeting
Bayer announced a new post hoc sub-analysis of key secondary endpoint data from the OASIS-1 and OASIS-2 pivotal trials for Lynkuet (elinzanetant) 60mg capsules at 2026 The Menopause Society (TMS) Annu...
China approves Bayer blood thinner asundexian
China's drug regulator said on Monday it approved the blood thinner asundexian from Bayer , a potential boost for the German drugmaker in the world's second-largest pharmaceutical market as it moves
Bayer Gets in China Its First Global Approval for Stroke Prevention Drug
The decision hands Bayer the first ever approval for a Factor XIa inhibitor, which aim to slow the activity of a protein that regulates how the body forms clots without increasing the risk of bleeding...
ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA® plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence.
ESMO 2026: NUBEQA (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical Trials Group at the European Society for Medical Oncology (ESMO) Congress 2026 w...
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failur...
Bayer partners with actress Melissa Joan Hart to increase awareness of Lynkuet
Bayer (BAYRY) announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment...
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's FD...
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet (elinzanetant) 60mg capsules, Bayer’s FDA-approved, hormone-free prescript...
Bayer announces FDA acceptance of Kerendia sNDA
Bayer (BAYRY) announced that the FDA accepted the company’s supplemental new drug application, or sNDA, for Kerendia, which is being investigated for the treatment of adults with chronic kidney diseas...